AgingResearch.NewsJoin free

Stemregenin 1

Intervention

1 paper3 findings

PubChem 46199207ChEBI 230484MeSH C552240

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: American Heart Association and 7 more
  • Animals1

Outcomes

3

Cellular senescence

downin human cells1

1 study

  1. Stemregenin 1 prevents cellular senescence in human cells.

    “recruiting hibernating ECs to accompany expanding EC populations without imposing replicative senescence”

    Cellsin expanded human ECs

    A non-canonical aryl hydrocarbon receptor pathway authorizes and safeguards clinical-scale expansion of functional human endothelial cells

    Nature cardiovascular research14 Oct 2025

More on Cellular senescence

Expansion of primary human adipose ECs

upin human cells1

1 study

  1. Stemregenin 1 increases expansion of primary human adipose ECs in human cells (100-fold).

    “AHR inhibitors induced 100-fold greater expansion of 200,000 primary human adipose ECs to 2.4 × 1012 ECs”

    Cellsendothelial cells

    A non-canonical aryl hydrocarbon receptor pathway authorizes and safeguards clinical-scale expansion of functional human endothelial cells

    Nature cardiovascular research14 Oct 2025

EC proliferation

upin human cells1

1 study

  1. Stemregenin 1 increases EC proliferation in human cells (3-fold).

    “Incubation of tissue-specific human ECs with AHR inhibitors, such as StemRegenin1 (SR1), increased EC proliferation by three-fold within an 8-day period.”

    Cellsendothelial cells8-day period

    A non-canonical aryl hydrocarbon receptor pathway authorizes and safeguards clinical-scale expansion of functional human endothelial cells

    Nature cardiovascular research14 Oct 2025

Latest

Related